New paper proposes tackling aging organ by organ, cell by cell, using proactive, systemic therapies based on replacement rather than repair.
What if, rather than striving to unravel aging’s every molecular cause, we simply replaced its effects? That is the question at the heart of a new Perspective published in Nature Aging by Sierra Lore, Jesse Poganik, Anthony Atala, George Church, Vadim Gladyshev, Morten Scheibye-Knudsen and Eric Verdin. In the paper, the authors propose a unified framework for approaching aging through replacement – biological and synthetic – and argue that many of the technologies needed to do so already exist, if not in practice, then in proof-of-concept [1].
The idea is at once familiar and quietly disruptive. Transplants, prosthetics, cell therapies and brain–machine interfaces are all widely accepted tools in modern medicine, but they are generally reserved for acute disease or end-stage failure. The authors propose something different: the strategic, even preventative, use of these tools to combat aging itself– not by repairing the old, but by installing the new.
Replacement as a philosophy of longevity
This shift in perspective moves the field from searching for silver-bullet interventions to a more modular view of human biology. Rather than attempting to slow all aspects of decline simultaneously, replacement targets specific failures – joint, pancreas, hippocampus – and swaps them for functional alternatives. The approach is not limited to biological materials; synthetic devices, from pacemakers to neural implants, are given equal consideration.
“This enduring uncertainty [about the cause of aging] has inspired a shift away from strategies that solely aim to slow or repair molecular damage,” write the authors, “toward innovative approaches that replace compromised tissues and systems with engineered alternatives [1].”
The proposed framework maps replacement interventions across two axes: biological and synthetic on one, and cellular, organ/tissue and brain on the other. On the biological side, this includes cell therapy, tissue engineering, bioprinting and xenotransplantation; on the synthetic side, prostheses, external devices and brain–machine interfaces. It is a tidy schema, yet it reflects decades of disparate technological development – now slowly converging around the problem of age-related decline.
Longevity.Technology: This Perspective offers a timely and thought-provoking synthesis, reframing a familiar toolkit of medical interventions – transplants, prosthetics, bioprinting – as a coherent strategy for combating aging itself. With companies like Somite AI using machine learning to industrialize cell therapies, and LongGame’s recent investment in Renewal Bio pushing the frontier of synthetic embryology, it’s clear that the replacement paradigm is no longer confined to theory. This conceptual unification matters: if aging is understood as the progressive failure of component parts – of tissues, cells, circuits – then managing aging may become less about solving biology’s grand riddles and more about mastering logistics and engineering. The idea is almost shockingly pragmatic: replace what wears out, when it does.
What might follow is a new class of interventions – preventative replacements, modular upgrades and bio-integrated devices deployed long before catastrophic failure. As the authors put it: “Rather than addressing each deteriorative process in isolation, these emerging replacement-based strategies offer a promising avenue to restore functionality and overcome the limitations of conventional interventions [1].” The idea is decidedly pragmatic – almost disarmingly so: replace what wears out, when it does. For the clinic, this opens up the prospect of tissue maintenance schedules rather than crisis interventions. For industry, it’s a signal to invest in scalable platforms: perfusion systems, cryopreservation, iPSC banks and ethical sourcing of donor tissues. And for regulators, it raises urgent questions about the governance of hybrid bio-synthetic therapies, access and equity.
Could we treat aging not as an inevitable entropic slide, but as a series of maintainable subsystems? If so, the challenge becomes not just biological, but infrastructural – how to manufacture, store, deliver and integrate the biological equivalents of spare parts at population scale. It’s a bold vision, but one grounded in existing technologies – and one that invites the longevity field to reimagine its strategy from first principles.
From spare parts to systems thinking
Importantly, the paper does not argue from first principles alone; it also reviews a body of evidence that supports the potential of replacement in an aging context. Heterochronic parabiosis – connecting the circulatory systems of young and old mice – has repeatedly demonstrated rejuvenating effects, including improved cognition and extended lifespan in aged animals [2]. Therapeutic plasma exchange in humans has begun to show similar promise, albeit in early-stage studies [3].
The age of donor organs, too, appears to matter. In transplants, older organs are associated with poorer outcomes in younger recipients, even when immune factors are controlled. “These observations highlight the effect of donor age on recipient health,” the authors note, “and underscore the need for further research into donor age and pre-existing damage [1].”
Still, the challenges of translating this framework into practice are significant. Organ and tissue replacement remains invasive, expensive and logistically demanding. Immunosuppression carries long-term risks. Cryopreservation of complex tissues is still in development. And the ethics of creating synthetic embryo-like models for cell sourcing remain unsettled, particularly as technologies like stembroids mature.
Toward a practical longevity engineering
Yet progress continues. Advances in bioreactors, perfusion systems and bioinks are making it more feasible to grow patient-specific tissues in controlled environments. The use of iPSCs and CRISPR to reduce rejection risk is already changing transplant immunology. Startups are exploring ways to grow organs ex vivo, while others look to wearable artificial kidneys and closed-loop insulin pumps as early harbingers of synthetic organ support.
One of the more intriguing areas is brain replacement. While a full transplant remains in the realm of speculative fiction, partial integration of stem cell-derived neurons into aged or damaged circuits is already underway. Devices like Neuralink’s wireless brain–machine interface represent an adjacent path, one that may become increasingly relevant as cognition becomes a target of preventative longevity interventions.
The authors are clear-eyed about the distance between concept and clinic – but equally clear that the distance is shortening.
A different kind of moonshot
If geroscience has long been preoccupied with the molecular hallmarks of aging, this paper suggests a complementary trajectory: building functional replacements for what inevitably breaks. It is a practical vision, but one that asks difficult questions of scale, ethics and equity.
And it may be, in its own way, quietly radical. For if aging can be managed not through elusive molecular mastery, but through the careful orchestration of bioengineering and logistics, then perhaps longevity is not just a biological problem – but also a systems one.
[1] https://www.nature.com/articles/s43587-025-00858-6
[2] https://pubmed.ncbi.nlm.nih.gov/37500973/
[3] https://www.medrxiv.org/content/10.1101/2024.08.02.24310303v1
